Part of Pluri, Inc., Pluristem Ltd. is a company headquartered in Haifa, Israel, that provides research and development services in the biotechnology field, especially in stem cell research. The firm was founded by Yoram Nathan Drucker. Pluri, Inc. acquired Pluristem Ltd. on June 23, 2003.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.

Histogen is a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body. The company’s innovative technology platform utilizes cell-conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address underserved, multi-billion US dollar global markets. It was founded in 2007 by Dr. Gail Naughton and is headquartered in San Diego, California.

BioGaia is an innovative Swedish health care company

Provides biotechnology and research services and develops cell therapy technology

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Fresenius Medical Care is a provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. It has a network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa. It offers specialty pharmacy and laboratory services and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. The company was founded in 1996 and is headquartered in Bad Homburg, Frankfurt.

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Stempeutics Research Pvt. Ltd. is a private company headquartered in Bangalore, India. The firm develops, commercializes and sells novel therapeutics products.\nThe company says this about itself: Stempeutics Research Bangalore is a late stage life science company focused on developing and commercializing novel therapeutics based on adult stem cells. It was founded by the Manipal Education and Medical Group in 2006. Stempeutics strength lies in developing innovative stem cell products by nurturing cutting edge research and clinical applications through dedicated efforts of its highly qualified team. Currently it is focusing on the following three innovative products: Stempeucel® drug, Stempeucare™ cosmetics and Stempeutron™ medical device.

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. The firm involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. They have four approved products on the market today and they are not stopping there! From the United States to Europe to the Asia Pacific, they are proud of their multicultural business environment where employees can collaborate with people all over the world. As a group, they are relentless in their pursuit of “medicines for life”® and continue their research into treatments for pulmonary arterial hypertension, cancer, and some of the world’s most complicated viral illnesses.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

StemLab is a Korean biotech company that is developing therapeutic solutions to treat diseases and injuries that have no alternative cures. In particular, it develops cells that can regenerate the central nervous system tissues based on its cell reprogramming technology that transforms somatic cells into stem cells. Stemlab’s cell reprogramming technology takes fully differentiated cells and reprograms them into neural stem cells, allowing them to obtain the stem cells necessary to create stem cell therapies. It thus avoids the ethical issues concernng embryonic stem cell research. Also, its reprogrammed neural stem cells have expansion capability comparable to neural stem cells derived from pluripotent stem cells. And since StemLab obtains somatic cells through urine, harvesting is much less invasive than using cells obtained using other invasive means. StemLab's technology is backed up with 18 patents for original technology related to stem cell treatments and has three patents for application technology, with another five pending. Its initial clinical programs will involve patients with spinal cord injury (SCI) and Amyotrophic Lateral Sclerosis (ALS) or (Lou Gehrig's Disease.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Corion Biotech is a biotech company developing innovative therapeutic solutions for Women's Health. Its technology is based on a specific cell population derived from the human term placenta known as Placental Mesenchymal Stromal Cells (hPDMSCs).

SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.